Related Experiment Video
Updated: Jul 8, 2025

A Strategy for Sensitive, Large Scale Quantitative Metabolomics
Published on: May 27, 2014
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working
Wenkui Li1, Faye Vazvaei-Smith2, Gordon Dear3
1Pharmacokinetic Sciences, Novartis Biomedical Research, East Hanover, New Jersey, USA.
Abstract:
The intent of this perspective is to share the recommendations of the International Consortium for Innovation and Quality in Pharmaceutical Development Metabolite Bioanalysis Working Group on the fit-for-purpose metabolite bioanalysis in support of drug development and registration. This report summarizes the considerations for the trigger, timing, and rigor of bioanalysis in the various assessments to address unique challenges due to metabolites, with respect to efficacy and safety, which may arise during drug development from investigational new drug (IND) enabling studies, and phase I, phase II, and phase III clinical trials to regulatory submission. The recommended approaches ensure that important drug metabolites are identified in a timely manner and properly characterized for efficient drug development.
More Related Videos
05:35An Integrated Workflow of Identification and Quantification on FDR Control-Based Untargeted Metabolome
Published on: September 20, 2022
11:25Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis
Published on: July 11, 2014
Related Concept Videos
Drug Metabolism: Phase II Reactions
Drug Biotransformation: Overview
Drug Metabolism: Phase I Reactions